Introduction
Cisplatin is a widely used chemotherapy drug known for its ototoxicity. This study investigates the progression of cisplatin-related hearing loss (CRHL) in cancer survivors and its associated risk factors.
Key Findings
Hearing Loss Progression: In a cohort of 100 cancer survivors, significant hearing loss progression was noted, especially in those receiving higher doses of cisplatin.
Associated Risk Factors: Hypercholesterolemia, lower education, and severe CRHL were linked to poorer hearing performance.
Dose Interaction: Patients receiving 300 mg/m² or less experienced significantly less hearing loss progression compared to those receiving higher doses.
Conclusion
Regular audiological assessments and management of risk factors like hypercholesterolemia are crucial for cisplatin-treated cancer survivors. Tailoring follow-up care based on these findings can help mitigate hearing loss progression.
Original Study
https://doi.org/10.1001/jamaoncol.2024.1233
Get health updates from Dr Harsh Shah on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
Leave a Reply